Stock NSB NEUROSCIENTIFIC BIOPHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News NeuroScientific Biopharmaceuticals Limited

Equities

NSB

AU0000012973

Market Closed - Australian S.E.
Other stock markets
 02:10:05 2024-04-29 am EDT 		5-day change 1st Jan Change
0.052 AUD +8.33% Intraday chart for NeuroScientific Biopharmaceuticals Limited 0.00% +18.18%
Mar. 20 NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6% MT
Feb. 27 NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
NeuroScientific Biopharmaceuticals Secures AU$2 Million R&D Tax Rebate for Fiscal Year 2023; Shares Rise 6%
MT
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023
CI
NeuroScientific Biopharmaceuticals Limited Announces Changes to Board of Directors
CI
NeuroScientific Biopharmaceuticals CEO to Step Down
MT
NeuroScientific Biopharmaceuticals Limited Announces Resignation of Stephen Carter as CEO Effective 31 December 2023
CI
Linda Friedland Steps Down from the Board of NeuroScientific Biopharmaceuticals Limited, Effective 17 November 2023
CI
Neuroscientific Biopharmaceuticals Limited Announces Board Changes
CI
NeuroScientific Biopharmaceuticals Ltd Appoints Linda Friedland as Independent Non-Executive Director
CI
Neuroscientific Biopharmaceuticals Limited Announces Chief Executive Officer Changes
CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023
CI
Neuroscientific Biopharmaceuticals Announce Positive Treatment Effect in Multiple sclerosis Animal Study
CI
NeuroScientific Biopharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2022
CI
Neuroscientific Biopharmaceuticals Files New Patent for Multiple Sclerosis Treatment; Shares Jump 7%
MT
NeuroScientific Biopharmaceuticals Files A New Patent, Entitled "Neuroprotective Compositions and Methods"
CI
NeuroScientific Biopharmaceuticals Names Interim CEO; Shares Climb 12%
MT
NeuroScientific Biopharmaceuticals Limited Announces Appointment of Mr. Paul Rennie as Interim CEO
CI
NeuroScientific Biopharmaceuticals Limited Announces Management Changes
CI
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as Managing Director
CI
NeuroScientific Biopharmaceuticals Ltd Announces Resignation of Matt Liddelow as CEO
CI
Neuroscientific Biopharmaceuticals Ltd. Announces HREC Decision to Not Approve Phase I Clinical Trial
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NSB Stock
  4. News NeuroScientific Biopharmaceuticals Limited